应《网络安全法》要求，自2017年10月1日起，未进行实名认证将不得使用互联网跟帖服务。为保障您的帐号能够正常使用，请尽快对帐号进行手机号验证，感谢您的理解与支持！
药渡经纬信息科技（北京）有限公司
http://www.pharmacodia.com/
药渡网 Drug A-Z 《世界药物精览》 药渡微信
北京市海淀区上地五街7号昊海大厦一层105室
联系人: 牛红艳 / 邮箱: hongyan.niu@pharmacodia.com / QQ: 524103527 / 电话: 01082826195 / 手机: 13911948867
关注收听
小木虫论坛-学术科研互动平台 » 科研市场区 » 综合广告推广 » 其他 » 【转自药渡网】Teva 报告了乐观哮喘临床3期评估结果
1021/3返回列表123下一页
查看: 1768  |  回复: 101
只看楼主 @他人 存档 新回复提醒 (忽略) 收藏    在APP中查看

药渡

银虫 (小有名气)

[交流] 【转自药渡网】Teva 报告了乐观哮喘临床3期评估结果

Teva 对临床3期评估了对于哮喘患者干粉吸入器 (MDPIs)吸入Fluticasone Propionate /Salmeterol和多剂量Fluticasone Propionate 的实验效果，实验数据很好。研究表明通过使用干粉吸入器 (MDPI)，低剂量与安慰剂相比具有更大的效能，结果展示 Teva 扩大呼吸的研发能力和支持其核心，呼吸驱动MDPI平台的发展。最初的结果显示fluticasone propionate/salmeterol MDPI的不良事件可以和fluticasone propionate治疗和安慰剂媲美。

相关阅读：

Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma
Studies demonstrate greater efficacy with lower doses delivered via multidose dry-powder inhaler (MDPI) compared to placebo
Results showcase Teva’s expanding respiratory R&D capabilities and support advancement of core, breath-actuated MDPI platform
   Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced positive top-line results from three Phase III clinical studies designed to evaluate the efficacy and safety of fluticasone propionate/salmeterol, a combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) delivered via a multidose dry powder inhaler (MDPI) and fluticasone propionate, an ICS monotherapy delivered via a MDPI in adolescent and adult patients with asthma. Top-line data showed that the studies met their primary endpoints. Importantly, the studies also showed similar overall safety profiles as compared to therapies in the corresponding drug classes.

   “These data support Teva’s commitment to further optimize the treatment of respiratory disease through the development of devices and therapies that help address the needs of patients and physicians,” said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. “With this dual development program we have demonstrated clinically significant levels of effectiveness, by delivering combination and monotherapy at lower doses utilizing our core, breath-actuated, MDPI platform.”

   Fluticasone propionate/salmeterol MDPI demonstrated, in the double-blind studies, clinically relevant and greater benefit at all doses (50/12.5, 100/12.5, and 200/12.5 mcg BID nominal delivered doses) versus placebo and versus respective monotherapy (fluticasone propionate) in the improvement of lung function as measured by the change from baseline in trough Forced Expiratory Volume in one second (FEV1) at the 12-week trial period and standardized baseline-adjusted area under the effect curve FEV1 from time 0 to 12 hours post dose at Week 12. This initial set of results shows the adverse event profile of fluticasone propionate/salmeterol MDPI was comparable to fluticasone propionate monotherapy and placebo.

   Fluticasone propionate MDPI also demonstrated clinically relevant and greater benefit at all doses (50, 100, and 200 mcg BID nominal delivered doses) versus placebo in the improvement of lung function, in the double-blind studies. The initial set of results shows the adverse event profile of fluticasone propionate MDPI was comparable to placebo.

   The majority of adverse events were mild to moderate in severity. There were no drug-related deaths across any of the trials. Further analyses of additional efficacy and safety data are ongoing. Full results will be submitted for presentation at future scientific meetings and for publication in peer reviewed journals.

   “We have made significant progress in furthering our respiratory pipeline with a focus on a complete asthma management system utilizing our breath-actuated MDPI platform,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva. “We have successfully developed and launched products that utilize our breath-actuated MDPI platform in select markets around the world. These data support the broadening of our portfolio in using this technology to develop and deliver additional respiratory therapeutic options.”

   Regulatory submissions for both fluticasone propionate/salmeterol MDPI and fluticasone propionate MDPI in the U.S. are planned for 2016.
回复此楼

» 猜你喜欢

» 抢金币啦！回帖就可以得到:

查看全部散金贴
1楼 2015-11-20 15:40:41
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

wengcunz

禁虫 (著名写手)
★
药渡(金币+1): 谢谢参与
本帖内容被屏蔽
14楼2015-11-20 16:01:12
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
简单回复
sxln2楼
2015-11-20 15:48   回复  
药渡(金币+1): 谢谢参与
laom20133楼
2015-11-20 15:50   回复  
药渡(金币+1): 谢谢参与
miaojiabing4楼
2015-11-20 15:50   回复  
药渡(金币+1): 谢谢参与
10357505705楼
2015-11-20 15:50   回复  
药渡(金币+1): 谢谢参与
。 发自小木虫Android客户端
天涯20126楼
2015-11-20 15:51   回复  
药渡(金币+1): 谢谢参与
skyish7楼
2015-11-20 15:52   回复  
药渡(金币+1): 谢谢参与
laozhu55728楼
2015-11-20 15:54   回复  
药渡(金币+1): 谢谢参与
dmbb9楼
2015-11-20 15:57   回复  
药渡(金币+1): 谢谢参与
江南的竹10楼
2015-11-20 15:58   回复  
药渡(金币+1): 谢谢参与
。 [ 发自小木虫客户端 ]
chenchenyf11楼
2015-11-20 15:59   回复  
药渡(金币+1): 谢谢参与
xiejiaf12楼
2015-11-20 16:00   回复  
药渡(金币+1): 谢谢参与
feiyief13楼
2015-11-20 16:01   回复  
药渡(金币+1): 谢谢参与
mhycpxir15楼
2015-11-20 16:01   回复  
药渡(金币+1): 谢谢参与
irshvj16楼
2015-11-20 16:02   回复  
药渡(金币+1): 谢谢参与
kolimm17楼
2015-11-20 16:02   回复  
药渡(金币+1): 谢谢参与
祝福
am435918楼
2015-11-20 16:02   回复  
药渡(金币+1): 谢谢参与
wblxcs19楼
2015-11-20 16:02   回复  
药渡(金币+1): 谢谢参与
祝福
wnotffisg20楼
2015-11-20 16:03   回复  
药渡(金币+1): 谢谢参与
祝福
ahsjlyu21楼
2015-11-20 16:03   回复  
药渡(金币+1): 谢谢参与
.
keoxri22楼
2015-11-20 16:03   回复  
药渡(金币+1): 谢谢参与
vrxcyvkss23楼
2015-11-20 16:03   回复  
药渡(金币+1): 谢谢参与
,
ooxmfc24楼
2015-11-20 16:04   回复  
药渡(金币+1): 谢谢参与
ucmxjl25楼
2015-11-20 16:04   回复  
药渡(金币+1): 谢谢参与
,
bincmq26楼
2015-11-20 16:04   回复  
药渡(金币+1): 谢谢参与
祝福
fqmkia27楼
2015-11-20 16:04   回复  
药渡(金币+1): 谢谢参与
wxubpn28楼
2015-11-20 16:05   回复  
药渡(金币+1): 谢谢参与
祝福
iygbojqj29楼
2015-11-20 16:05   回复  
药渡(金币+1): 谢谢参与
sjtdeud30楼
2015-11-20 16:05   回复  
药渡(金币+1): 谢谢参与
shsvoy31楼
2015-11-20 16:05   回复  
药渡(金币+1): 谢谢参与
cmyfna32楼
2015-11-20 16:06   回复  
药渡(金币+1): 谢谢参与
sgadsdkc33楼
2015-11-20 16:06   回复  
药渡(金币+1): 谢谢参与
,
quainyni34楼
2015-11-20 16:06   回复  
药渡(金币+1): 谢谢参与
wbwwrs35楼
2015-11-20 16:06   回复  
药渡(金币+1): 谢谢参与
祝福
yuduoj36楼
2015-11-20 16:06   回复  
药渡(金币+1): 谢谢参与
支持
ofresq37楼
2015-11-20 16:06   回复  
药渡(金币+1): 谢谢参与
.
tanmingp38楼
2015-11-20 16:06   回复  
药渡(金币+1): 谢谢参与
qdjoupudwqx39楼
2015-11-20 16:06   回复  
药渡(金币+1): 谢谢参与
,
qyoycw40楼
2015-11-20 16:07   回复  
药渡(金币+1): 谢谢参与
fangfengw41楼
2015-11-20 16:07   回复  
药渡(金币+1): 谢谢参与
祝福
virologik42楼
2015-11-20 16:07   回复  
药渡(金币+1): 谢谢参与
liufeic43楼
2015-11-20 16:07   回复  
药渡(金币+1): 谢谢参与
xiachaz44楼
2015-11-20 16:07   回复  
药渡(金币+1): 谢谢参与
hodydo45楼
2015-11-20 16:07   回复  
药渡(金币+1): 谢谢参与
zhangfangp46楼
2015-11-20 16:07   回复  
药渡(金币+1): 谢谢参与
hudouz47楼
2015-11-20 16:07   回复  
药渡(金币+1): 谢谢参与
祝福
ffwmeg48楼
2015-11-20 16:07   回复  
药渡(金币+1): 谢谢参与
.
yushat49楼
2015-11-20 16:07   回复  
药渡(金币+1): 谢谢参与
qiyingy50楼
2015-11-20 16:07   回复  
药渡(金币+1): 谢谢参与
支持
相关版块跳转 我要订阅楼主 药渡 的主题更新
1021/3返回列表123下一页
普通表情 龙 兔 虎 猫 高级回复 (可上传附件)
信息提示
关闭
请填处理意见
关闭